sentences:
Distinct exosomal miRNA profiles from BALF and lung tissue from COPD and IPF patients BackgroundChronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) are chronic, progressive lung ailments which are characterized by distinct pathologies. Early detection biomarkers and disease mechanisms for these debilitating diseases are lacking. Exosomes are small extracellular vesicles attributed to carry proteins, mRNA, miRNA and sncRNA to facilitate cell-to-cell communication under normal and diseased conditions. Exosomal miRNAs have been studied in relation to many diseases. However, there is little to no knowledge regarding the miRNA population of BALF or the lung tissue derived exosomes in COPD and IPF. Here, we determined and compared the miRNA profiles of BALF and lung tissue-derived exosomes from healthy non-smokers, healthy smokers, and patients with COPD and IPF in independent cohorts.

ResultsExosome characterization using NanoSight particle tracking and TEM demonstrated that the BALF-derived exosomes were approximately 89.85 nm in size and [~]2.95 x 1010 particles/mL. Lung-derived exosomes were [~]146.04 nm in size and [~]2.38 x 1011 particles/mL. NGS results identified three differentially expressed miRNAs in the BALF, while one in the lung-derived exosomes from COPD patients as compared to healthy non-smokers. Of these, three- and five-fold downregulation of miR-122-5p amongst the lung tissue-derived exosomes from COPD patients as compared to healthy non-smokers and smokers, respectively. Interestingly, there were key 55 differentially expressed miRNAs in the lung tissue-derived exosomes of IPF patients compared to non-smoking controls.

ConclusionsOverall, we identified specific miRNAs to develop as biomarkers or targets for pathogenesis of these chronic lung diseases.


sentences:
Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers ObjectiveTo evaluate links between registration and publication across clinical trials led by German university medical centers (UMCs) and registered in either ClinicalTrials.gov or the German Clinical Trials Registry (DRKS). Inadequate links make trial publications and registrations less findable and compromise evidence synthesis and health policy decision making. The World Health Organization (WHO) and others call for better adoption of this straightforward transparency practice.

DesignCross-sectional bibliographic study

SettingGerman UMC clinical trials

MethodsWe used automated strategies to download and extract data from trial registries, PubMed, and trial publications for a cohort of all registered, published clinical trials conducted across German UMCs and completed between 2009 and 2017. We implemented regular expressions to detect and classify publication identifiers (DOI and PMID) in registrations, and trial registrations numbers (TRNs) in publication metadata, abstract, and full-text.

Main outcome measuresThe proportion of trial registrations that reference a known results publication. The proportion of results publications that report the known TRN in the metadata, abstract, and full-text.

Secondary analysesWe constructed exploratory logistic regression models to investigate the relationship between trial completion date, registry, and registration-publication linking.

ResultsOnly 20% (373/1,895) of trials have a linked publication (DOI or PMID) in the registration as well as the TRN in the publication full-text, abstract, and metadata, and only 25% (477) of trials met the CONSORT and ICMJE guidelines to include TRNs in both the full-text and the abstract. 17% (327) of trials had no links. The most common link was TRN reported in the full-text (60%, 1,137). ClinicalTrials.gov trials were overall better linked than DRKS trials, and this difference appears to be driven by PubMed and registry infrastructure, rather than by trialists. Of trials reporting a TRN in the abstract, trials in ClinicalTrials.gov were more likely than trials in DRKS to have the TRN captured in the PubMed metadata. Most (78%, 662/849) ClinicalTrials.gov registrations with a publication link were automatically indexed from PubMed metadata, which is not possible in DRKS.

ConclusionGerman UMCs have not comprehensively linked trial registrations and publications by both including a structured reference to the publication in the registration, and reporting TRNs in results publications. In addition to improved linking by trialists, changes in the PubMed TRN capturing process (such as automated strategies like those developed in this study) and automated indexing of publications in DRKS would make trial registrations and results more findable.

Open Data and CodeAll code and the final analysis data for this study are available at https://github.com/maia-sh/reg-pub-link. Raw data is available at https://github.com/maia-sh/intovalue-data.

labels: medical ethics


sentences:
Comparative Analysis of the Chemotherapy-related Cognition Impairments in Patients with Breast Cancer: a Community-based Research PurposeWith increasing breast cancer (BC) survival rates, the survivors quality of life (QoL) has become an important issue. Chemotherapy-induced cognitive impairment, known as "chemobrain" has been addressed recently. Therefore, cognitive function as one of the determinants of QoL should be considered while prescribing chemotherapeutics. In this study, we aimed to evaluate the effects of two common chemotherapy regimens on BC survivors cognition.

MethodsThe participants comprised 35 BC patients who underwent two common chemotherapy regimens, AC-T and TAC, and 24 matched healthy volunteers. The participants were assessed regarding anxiety, depression, general health status, and cognitive function including aspects of concentration, verbal ability, reasoning, memory, and visuospatial skill through Addenbrookes Cognitive Examination (ACE-P) and Cambridge Brain Science (CBS) tests.

ResultsRegarding depression and anxiety, there were no significant differences between the three groups. However, BC patients significantly complained of chronic fatigue compared to healthy volunteers (P-value = 0.027). Besides, ACE-P revealed the language domain to be affected in the AC-T group in comparison with the TAC-treated cases (P-value = 0.036). Moreover, the patients receiving the AC-T regimen had worse performance in visuospatial working memory and attention domains compared to the TAC group considering CBS tests (P-value = 0.031 and 0.008, respectively).

ConclusionThe results represent the AC-T regimen to be more toxic than the TAC in domains of language, concentration, and visuospatial working memory.

Implications for cancer survivorsThe AC-T regimen should be prescribed with caution in BC patients suffering from baseline cognitive impairments to improve post-chemotherapy QoL.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=149 SRC="FIGDIR/small/21262481v2_ufig1.gif" ALT="Figure 1">
View larger version (39K):
org.highwire.dtl.DTLVardef@242c7eorg.highwire.dtl.DTLVardef@e53ba9org.highwire.dtl.DTLVardef@1aff274org.highwire.dtl.DTLVardef@56adec_HPS_FORMAT_FIGEXP  M_FIG C_FIG

labels: neurology


sentences: Predicting COVID-19 Incidences from Patients Viral Load using Deep-Learning The transmission of the contagious COVID-19 is known to be highly dependent on individual viral dynamics. Since the cycle threshold (Ct) is the only semi-quantitative viral measurement that could reflect infectivity, we utilized Ct values to forecast COVID-19 incidences. Our COVID-19 cohort (n=9531), retrieved from a single representative cross-sectional virology test center in Lebanon, revealed that low daily mean Ct values are followed by an increase in the number of national positive COVID-19 cases. A subset of the data was used to develop a deep neural network model, tune its hyperparameters, and optimize the weights for minimal mean square error of prediction. The final models accuracy is reported by comparing its predictions with an unseen dataset. Our model was the first to capture the interaction of the previously reported Ct values with the upcoming number of COVID-19 cases and any temporal effects that arise from population dynamics. Our model was deployed as a publicly available and easy-to-use estimator to facilitate prospective validation. Our model has potential application in predicting COVID-19 incidences in other countries and in assessing post-vaccination policies. Aside from emphasizing patient responsibility in adopting early testing practices, this study proposed and validated viral load measurement as a rigid input that can enhance outcomes and precision of viral disease predicting models.

labels: health informatics


sentences:
An in-depth statistical analysis of the COVID-19 pandemic's initial spread in the WHO African region During the first wave of the COVID-19 pandemic, sub-Saharan African countries experienced comparatively lower rates of SARS-CoV-2 infections and related deaths than in other parts of the world, the reasons for which remain unclear. Yet, there was also considerable variation between countries. Here, we explored potential drivers of this variation among 46 of the 47 World Health Organization African region member states in a cross-sectional study. We described five indicators of early COVID-19 spread and severity for each country as of 29 November 2020: delay in detection of the first case, length of the early epidemic growth period, cumulative and peak attack rates, and crude case fatality ratio (CFR). We tested the influence of 13 pre-pandemic and pandemic response predictor variables on the country-level variation in the spread and severity indicators using multivariate statistics and regression analysis. We found that wealthier African countries, with larger tourism industries and older populations, had higher peak (p < 0.001) and cumulative (p < 0.001) attack rates, and lower CFRs (p = 0.021). More urbanized countries also had higher attack rates (p < 0.001 for both indicators). Countries applying more stringent early control policies experienced greater delay in detection of the first case (p < 0.001), but the initial propagation of the virus was slower in relatively wealthy, touristic African countries (p = 0.023). Careful and early implementation of strict government policies were likely pivotal to delaying the initial phase of the pandemic, but did not have much impact on other indicators of spread and severity. An over-reliance on disruptive containment measures in more resource-limited contexts is neither effective nor sustainable. We thus urge decision-makers to prioritize the reduction of resource-based health disparities, and surveillance and response capacities in particular, to ensure global resilience against future threats to public health and economic stability.

Summary BoxO_ST_ABSWhat is already known on this topic?C_ST_ABSO_LICOVID-19 trajectories varied widely across the world, and within the African continent.
C_LIO_LIThere is significant heterogeneity in the surveillance and response capacities among WHO African region member states.
C_LI

What are the new findings?O_LICumulative and peak attack rates during the first wave of COVID-19 were higher in WHO African region member states with higher per-capita GDP, larger tourism industries, older and more urbanized populations, and higher pandemic preparedness scores.
C_LIO_LIAlthough better-resourced African countries documented higher attack rates, they succeeded in limiting rapid early spread and mortalities due to COVID-19 infection.
C_LIO_LIAfrican countries that had more stringent early COVID-19 response policies managed to delay the onset of the outbreak at the national level. However, this phenomenon is partially explained by a lack of detection capacity, captured in low pandemic preparedness scores, and subsequent initial epidemic growth rates were slower in relatively well-resourced countries.
C_LI

What do the new findings imply?Careful implementation of strict government policies can aid in delaying an epidemic, but investments in public health infrastructure and pandemic preparedness are needed to better mitigate its impact on the population as a whole.

labels: epidemiology


sentences: COVID-19 in Scottish care homes: A metapopulation model of spread among residents and staff Care homes in the UK were disproportionately affected by the first wave of the COVID-19 pandemic, accounting for almost half of COVID-19 deaths over the course of the period from 6th March - 15th June 2020. Understanding how infectious diseases establish themselves throughout vulnerable communities is crucial for minimising deaths and lowering the total stress on the National Health Service (NHS Scotland). We model the spread of COVID-19 in the health-board of NHS Lothian, Scotland over the course of the first wave of the pandemic with a compartmental Susceptible - Exposed - Infected reported - Infected unreported - Recovered - Dead (SEIARD), metapopulation model. Care home residents, care home workers and the rest of the population are modelled as subpopulations, interacting on a network describing their mixing habits. We explicitly model the outbreaks reproduction rate and care home visitation level over time for each subpopulation, and execute a data fit and sensitivity analysis, focusing on parameters responsible for intra-subpopulation mixing: staff sharing, staff shift patterns and visitation. The results suggest that hospital discharges were not predominantly responsible for the early outbreak in care homes, and that only a few such cases led to infection seeding in care homes by the 6th of March Sensitivity analysis show the main mode of entry into care homes are infections by staff interacting with the general population. Visitation (before cancellation) and staff sharing were less significant in affecting outbreak size. Our model suggests that focusing on the protection and monitoring of staff, followed by reductions in staff sharing and quick cancellations of visitation can significantly reduce future infection attack rates of COVID-19 in care homes.


sentences:
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar BACKGROUNDWaning of vaccine protection against SARS-CoV-2 infection or COVID-19 disease is a concern. This study investigated persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the Beta and Delta variants have dominated incidence and PCR testing is done at a mass scale.

METHODSA matched test-negative, case-control study design was used to estimate vaccine effectiveness against SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19 disease, between January 1, 2021 to August 15, 2021.

RESULTSEstimated BNT162b2 effectiveness against any infection, asymptomatic or symptomatic, was negligible for the first two weeks after the first dose, increased to 36.5% (95% CI: 33.1-39.8) in the third week after the first dose, and reached its peak at 72.1% (95% CI: 70.9-73.2) in the first five weeks after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating [≥]15 weeks after the second dose, reaching diminished levels of protection by the 20th week. Effectiveness against symptomatic infection was higher than against asymptomatic infection, but still waned in the same fashion. Effectiveness against any severe, critical, or fatal disease increased rapidly to 67.7% (95% CI: 59.1-74.7) by the third week after the first dose, and reached 95.4% (95% CI: 93.4-96.9) in the first five weeks after the second dose, where it persisted at about this level for six months.

CONCLUSIONSBNT162b2-induced protection against infection appears to wane rapidly after its peak right after the second dose, but it persists at a robust level against hospitalization and death for at least six months following the second dose.


sentences:
Depression Remission and Response Rates and Anxiety Response as a Predictor of Depression Response in a Community ECT Clinic ObjectiveTo assess depression response and remission rates with electroconvulsive therapy (ECT) in a community clinic and to identify factors predicting success in treatment.

MethodsWe identified 35 patients by a retrospective chart review with a diagnosis of major depressive disorder or depressive disorder not otherwise specified (according to the Diagnostic and Statistical Manual of Mental Disorders IV-TR) who were treated with an acute series of ECT at the Pine Rest ECT Clinic from March, 2014 to March, 2015. Clinical variables, demographics, depression response rates (based on Patient Health Questionnaire-9; PHQ-9), and anxiety response rates (based on Generalized Anxiety Disorder 7-item) were analyzed.

ResultsDepression response (defined as [≥] 50% reduction in PHQ-9 score) and remission rates (defined as final PHQ-9 score < 5) were 54.3% and 31.4%, respectively. This was a highly treatment resistant sample, with an average of 5.3 antidepressant failures prior to initiating ECT. Logistic regression analysis found that depression response rates were predicted by an improvement in anxiety symptoms (odds ratio 1.41; 95% confidence interval, 1.11, 1.78). Additionally, patients with initial severe anxiety scores were less likely than other patients to exhibit a response in depression (p = .027).

ConclusionAlmost half of this sample of patients with treatment resistant depression did not respond to ECT in this community-based clinic. Patients who experienced a response in anxiety symptoms were more likely to experience a depression response while those with severe anxiety were less likely to respond.

labels: psychiatry and clinical psychology


sentences:
Characterisation of type 2 diabetes subgroups and their association with ethnicity and clinical outcomes: a UK real-world data study using the East London Database BackgroundSubgroups of type 2 diabetes (T2DM) have been well characterised in experimental studies. However, it is unclear whether T2DM subgroups can be identified in UK based real-world populations and if they impact clinical outcomes.

AimTo derive T2DM subgroups using primary care data from a multi-ethnic population, evaluate associations with glycaemic control, treatment initiation and vascular outcomes, and understand how these vary by ethnicity.

Design and settingAn observational cohort study in the East London Primary Care Database from 2008-2018.

MethodLatent class analysis using age, sex, glycated haemoglobin, and body mass index at diagnosis was used to derive T2DM subgroups in White, South Asian, and Black groups. Time to treatment initiation and vascular outcomes was estimated using multivariable Cox-proportional hazards regression.

Results31,931 adults with T2DM were included: 47% south Asian, 25% White, 20% Black. We replicated two previously described subgroups,  Mild Age-Related Diabetes (MARD),  Mild Obesity-related Diabetes (MOD), and characterised a third  Severe Hyperglycaemic Diabetes (SHD). Compared to MARD, SHD had the poorest long term glycaemic control, fastest initiation of antidiabetic treatment (HR 2.02, 1.76-2.32), and highest risk of microvascular complications (HR 1.38, 1.28-1.49). MOD had the highest risk of macrovascular complications (HR 1.50, 1.23-1.83). Subgroup differences in treatment initiation were most pronounced for the White group, and vascular complications for the Black group.

ConclusionsClinically useful T2DM subgroups, identified at diagnosis, can be generated in routine real-world multi-ethnic populations, and may offer a pragmatic means to develop stratified primary care pathways and improve healthcare resource allocation.

How this fits inPrevious studies of predominantly White European populations have identified four T2DM subgroups. In the UK the clinical measures necessary to replicate these subgroups are only available in secondary care data, limiting their usefulness for diabetes management in primary care settings. In this study, we demonstrate how clinically meaningful T2DM subgroups can be pragmatically generated using real-world primary care data. Furthermore, we highlight important differences between T2DM subgroups with respect to vascular outcomes, treatment initiation, and HbA1c control. Diabetes subgroups are a useful heuristic for helping clinician decision-making which, in turn, this can lead to a more personalised design of diabetes care focussed on more intensive management of subgroups most at risk of complications, such as those with severe hyperglycaemia at time of diagnosis.


sentences:
Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα BackgroundPatients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF) biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear.

Aimto assess immune responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC).

MethodsProspective, controlled, multi-center Israeli study. Subjects enrolled received two BNT162b2 (Pfizer/BioNTech) doses. Anti-spike (S) antibodies levels and functional activity, anti-TNF levels and adverse events (AEs) were detected longitudinaly.

ResultsOverall 258 subjects: 185 IBD (67 treated with anti-TNF), and 73 HC. After the first vaccine dose all HC were seropositive, while some patients with IBD, regardless of treatment, remained seronegative. After the second dose all subjects were seropositive, however anti-S levels were significantly lower in anti-TNF treated compared to untreated patients, and HC (p<0.001; p<0.001, respectively). Neutralizing and inhibitory functions were both lower in anti-TNF treated compared to untreated patients, and HC (p<0.03; p<0.0001, respectively). Anti-TNF drug levels and vaccine responses did not affect anti-S levels. Infection rate ([~]2%) and AEs were comparable in all groups. IBD activity did not change in response to BNT162b2.

ConclusionsIn this prospective study in patients with IBD stratified according to treatment all patients mounted an immune response to two doses of BNT162b2. However, its magnitude was significantly lower in patients treated with anti-TNF, regardless of administration timing and drug levels. Vaccine was safe. As vaccine immune response longevity in this group may be limited, vaccine booster dose should be considered.

labels: gastroenterology


sentences:
Racial discrimination and covid-19 vaccine uptake: is mistrust of the health service behind vaccine refusal? ObjectiveTo examine whether racial/ethnic discrimination predicts future COVID-19 vaccine refusal, and whether this association is explained by trust in government and the health system.

DesignLongitudinal observational study of racial/ethnic discrimination occurring since the start of the first lockdown (measured in July 2020) and later COVID-19 vaccine status.

SettingUK (England, Scotland, Wales, and Northern Ireland)

Participants633 adults belonging to ethnic minority groups who took part in the UCL COVID-19 Social Study.

Main outcome measureCOVID-19 vaccine refusal (vs accepted/waiting/had at least one dose) between 23 December 2020 and 14 June 2021.

ResultsNearly one in ten (6.7%) who had refused a COVID-19 vaccine had experienced racial/ethnic discrimination in a medical setting since the start of the pandemic and had experienced twice as many incidents of racial/ethnic discrimination than those who had accepted the vaccine. Structural equation modelling results indicated a nearly 4-fold (odds ratio [OR] = 3.9, 95% confidence interval [CI] = 1.4 to 10.9) total effect of racial/ethnic discrimination on refusing the vaccine was which was mediated by low trust in the health system to handle the pandemic (OR = 2.5, 95% CI = 1.1 to 5.4). Analyses adjusted for a range of demographic and COVID-19 related factors.

ConclusionsFindings underscore the importance of addressing racial/ethnic discrimination and the role the National Health Service in regaining trust from ethnic minority groups to increase COVID-19 vaccine uptake amongst ethnic minority adults.

labels: public and global health


sentences:
Differentials and determinants of immunization coverage among children aged 12-36 months in India: Analysis of nationally-representative, population-based survey data IntroductionImmunization coverage among children is still a major public health concern in India and other low-middle income countries. Low coverage likely risks the health of children and therefore impacts their overall growth. We therefore examined the immunization coverage rates among children aged 12-36 months in India and its states. We also explored the associated factors affecting immunization coverage among children aged 12-36 in India.

MethodsWe used data from 75th round of the National Sample Survey Organizations (NSSO), collected from July 2017 to June 2018. The analytical sample of children aged 12-36 months information cases was 15887. Immunization coverage rates of India and its states were calculated. We evaluated the immunization coverage rate by background characteristics in India and its states. We performed multinomial logistic regression analysis to estimate the factors associated with the immunization coverage in India.

ResultsAbout 61.95% were fully immunized, 35.62% were partially immunized and the rest 2.43% had not received any vaccine. The children aged 21-28 months (0.50; p<0.01) & 29-36 months (0.35; p<0.01), belonging to North-Eastern regions (0.60; p<0.01) were found to be significantly less likely to receive fully immunization. Likewise, urban children are (1.26; p<0.1) found to be more likely to receive fully immunization. The lowest fully immunization has been seen in Daman and Diu (1.73%) followed by Nagaland (6.93%), NCT Delhi (34.71%), and Tripura (46.33%).

ConclusionsChild immunization is a key public health concern and vital challenge to be addressed. Socio-economic characteristics play a key role in immunization coverage. Therefore necessary policy measures must be taken to address the challenges of poor immunization coverage and its impact on health and wellbeing of children


sentences:
Father absence and trajectories of offspring mental health across adolescence and young adulthood: findings from a UK-birth cohort BackgroundHigh prevalence of parental separation and resulting biological father absence raises important questions regarding its impact on offspring mental health across the life course. However, few studies have examined prospective associations between biological father absence in childhood and risk of offspring depression and depressive symptoms trajectories across adolescence and young adulthood. We specifically examined whether these relationships vary by sex and the timing of exposure to father absence (early or middle childhood).

MethodsThis study is based on up to 8,409 children from the Avon Longitudinal Study of Parents and Children (ALSPAC). Participants provided self-reports of depression (Clinical Interview Schedule-Revised) at age 24 years and depressive symptoms (Short Mood and Feelings Questionnaire) between the ages of 10 and 24 years. Biological father absence in childhood was assessed through maternal questionnaires at regular intervals from birth to 10 years. We used logistic regression to examine the association between biological father absence and depression/depressive symptoms at age 24. We estimated the association between biological father absence and trajectories of depressive symptoms using multilevel growth-curve modelling.

ResultsEarly but not middle childhood father absence was strongly associated with increased odds of offspring depression and greater depressive symptoms at age 24 years. Early childhood father absence was associated with higher trajectories of depressive symptoms during adolescence and early adulthood compared with father presence. Differences in the level of depressive symptoms between middle childhood father absent and father present groups narrowed into early adulthood. Girls whose father was absent in early childhood, compared with present, manifested higher levels of depressive symptoms throughout adolescence, but this difference narrowed by early adulthood. In contrast, boys who experienced father absence in early childhood had similar trajectories of depressive symptoms compared to the father present group but experienced a steep increase in early adulthood. Girls whose fathers were absent in middle childhood manifested higher trajectories across middle adolescence into young adulthood compared to the father present group.

ConclusionsWe found evidence that father absence in childhood is persistently associated with offspring depression in adolescence and early adulthood and that this relationship varies by sex and timing of fathers departure. Further research is needed to examine whether this relationship is causal and to identify mechanisms that could inform preventative interventions to reduce the risk of depression in children who experience father absence.


sentences:
An automatic diagnostic system for pediatric genetic disorders developed by linking genotype and phenotype information BackgroundQuantitatively describe the phenotype spectrum of pediatric disorders has remarkable power to assist genetic diagnosis. Here, we developed a matrix which provide this quantitative description of genomic-phenotypic association and constructed an automatic system to assist the diagnose of pediatric genetic disorders.

Results20,580 patients with genetic diagnostic conclusions from the Childrens Hospital of Fudan University during 2015 to 2019 were reviewed. Based on that, a phenotype spectrum matrix -- cGPS (clinical Genes Preferential Synopsis) -- was designed by Naive Bayes model to quantitatively describe genes contribution to clinical phenotype categories. Further, for patients who have both genomic and phenotype data, we designed a ConsistencyScore based on cGPS. ConsistencyScore aimed to figure out genes that were more likely to be the genetic causal of the patients phenotype and to prioritize the causal gene among all candidates. When using the ConsistencyScore in each sample to predict the causal gene for patients, the AUC could reach 0.975 for ROC (95% CI 0.972-0.976 and 0.575 for precision-recall curve (95% CI 0.541-0.604). Further, the performance of ConsistencyScore was evaluated on another cohort with 2,323 patients, which could rank the causal gene of the patient as the first for 75.00% (95% CI 70.95%-79.07%) of the 296 positively genetic diagnosed patients. The causal gene of 97.64% (95% CI 95.95%-99.32%) patients could be ranked within top 10 by ConsistencyScore, which is much higher than existing algorithms (p <0.001).

ConclusionscGPS and ConsistencyScore offer useful tools to prioritize disease-causing genes for pediatric disorders and show great potential in clinical applications.

labels: pediatrics


sentences: Altered resting-state functional connectivity in hiPSC-derived neuronal networks from schizophrenia patients Schizophrenia (SZ) is a complex mental disease thought to arise from abnormal neurodevelopment, characterized by an altered reality perception and widely associated with brain connectivity anomalies. Previous work has shown disrupted resting-state brain functional connectivity (FC) in SZ patients. We used Human Induced Pluripotent Stem Cells (hiPSC)-derived neuronal cultures to study SZs neural communicational dynamics during early development. We conducted gene and protein expression profiling, calcium imaging and mathematical modeling to evaluate FC. Along the neurodifferentiation process, SZ networks displayed altered expression of genes related to synaptic function, cell migration and cytoskeleton organization, suggesting alterations in excitatory/inhibitory balance. Resting-state FC in neuronal networks derived from healthy controls (HC) and SZ patients emerged as a dynamic phenomenon exhibiting "hub-states", which are connectivity configurations reoccurring in time. Compared to HC, SZ networks were less thorough in exploring different FC configurations, changed configurations less often, presented a reduced repertoire of hub-states and spent longer uninterrupted time intervals in this less diverse universe of hubs. Our observations at a single cell resolution may reflect intrinsic dynamical principles ruling brain activity at rest and highlight the relevance of identifying multiscale connectivity properties between functional brain units. We propose that FC alterations in SZ patients are a consequence of an abnormal early development of synaptic communication dynamics, compromising networks ability for rapid and efficient reorganization of neuronal activity patterns. Remarkably, these findings mirror resting-state brain FC in SZ patients, laying the groundwork for future studies among such different spatiotemporal domains, as are brains and neurons, in both health and disease.


sentences:
Assessing the impact of community-based interventions on hypertension and diabetes management in three Minnesota communities: findings from the prospective evaluation of US HealthRise programs BackgroundCommunity-based health interventions are increasingly viewed as models of care that can bridge healthcare gaps experienced by underserved communities in the United States (US). With this study, we sought to assess the impact of such interventions, as implemented through the US HealthRise program, on hypertension and diabetes among underserved communities in Hennepin, Ramsey, and Rice Counties, Minnesota.

Methods and findingsHealthRise patient data from June 2016 to October 2018 were assessed relative to comparison patients in a difference-in-difference analysis, quantifying program impact on reducing systolic blood pressure (SBP) and hemoglobin A1c, as well as meeting clinical targets (< 140 mmHg for hypertension, < 8% Al1c for diabetes), beyond routine care. For hypertension, HealthRise participation was associated with SBP reductions in Rice (6.9 mmHg [95% confidence interval: 0.9-12.9]) and higher clinical target achievement in Hennepin (27.3 percentage-points [9.8-44.9]) and Rice (17.1 percentage-points [0.9 to 33.3]). For diabetes, HealthRise was associated with A1c decreases in Ramsey (1.3 [0.4-2.2]). Qualitative data showed the value of home visits alongside clinic-based services; however, challenges remained, including community health worker retention and program sustainability.

ConclusionsHealthRise participation had positive effects on improving hypertension and diabetes outcomes at some sites. While community-based health programs can help bridge healthcare gaps, they alone cannot fully address structural inequalities experienced by many underserved communities.


sentences:
Willingness and influential factors of parents to vaccinate their children against the COVID-19: a systematic review and meta-analysis BackgroundCoronavirus disease 2019 (COVID-19) vaccine uptake among children will be critical in limiting the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease. Parents are key decision-makers for whether their children will receive a COVID-19 vaccine.

ObjectiveTo estimate parents willingness to vaccinate their children against the COVID-19, and to investigate the predictors for their decision.

MethodsWe followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for this systematic review and meta-analysis. We searched Scopus, Web of Science, Medline, PubMed, ProQuest, and CINAHL from inception to August 11, 2021. The review protocol was registered with PROSPERO (CRD42021273125). We applied a random effect model to estimate pooled effects since the heterogeneity was very high. We used subgroup analysis and meta-regression analysis to explore sources of heterogeneity.

ResultsWe found 17 studies including 45,783 parents. The overall proportion of parents that intend to vaccinate their children against the COVID-19 was 56.8% (95% confidence interval: 51.8-61.8%). Parents willingness ranged from 29% to 72.7%. Studies quality, sample size, data collection time, and the continent that studies were conducted did not affect the results. The main predictors of parents intention to vaccinate their children against COVID-19 were male gender, older age of parents and children, higher socio-economic status, white race, positive attitudes toward vaccination, higher levels of knowledge, and higher levels of perceived threat from the COVID-19, worry, fear, and anxiety.

ConclusionsParents willingness to vaccinate their children against the COVID-19 is moderate and several factors affect this decision. Understanding parental COVID-19 vaccine hesitancy does help policy makers to change the stereotypes and establish broad community COVID-19 vaccination. Identification of the factors that affect parents willingness to vaccinate their children against COVID-19 will provide opportunities to enhance parents trust in the COVID-19 vaccines and optimize childrens uptake of a COVID-19 vaccine.


sentences:
Impact of Covid-19 Pandemic on Racial/Ethnic Differences in Mortality by Cause of Death ObjectivesTo quantify changes in all-cause and cause-specific mortality by race and ethnicity between 2019 and 2020.

MethodsUsing 2019 and 2020 provisional death counts from the National Center for Health Statistics and population estimates from the US Census Bureau, we estimate age-standardized death rates by race/ethnicity and attribute changes in mortality to various causes of death. We also examine how patterns of change across racial/ethnic groups vary by age and sex.

ResultsCovid-19 death rates in 2020 were highest in the Hispanic community whereas Black individuals had the largest increase in all-cause mortality between 2019 and 2020. Increases in mortality from heart disease, diabetes, and external causes of death accounted for the adverse trend in all-cause mortality within the Black population. Percentage increases in all-cause mortality were similar for men and women and for ages 25-64 and 65+ for Black and White populations, but increases were greatest for working-aged men among the Hispanic population.

ConclusionsExamining increases in non-Covid-19 causes of death is essential for fully capturing both the direct and indirect impact of the Covid-19 pandemic on racial/ethnic mortality disparities.


sentences:
Trends in Racial and Ethnic Disparities in Multimorbidity Prevalence, 1999-2018 BackgroundDisparities in multimorbidity prevalence indicate health inequalities. This study sought to determine if gaps in multimorbidity prevalence by race and ethnicity are decreasing over time.

Methods and findingsSerial cross-sectional analysis of the National Health Interview Survey from years 1999 to 2018. The study included individuals [≥]18 years old, categorized by self-reported race, ethnicity, age, and income. The main outcomes were temporal trends in multimorbidity prevalence based on the self-reported presence of [≥]2 of 9 chronic conditions. The study sample included 596,355 individuals (4.7% Asian, 11.8% Black, 13.8% Latino/Hispanic, and 69.7% White). In 1999, the estimated prevalence of multimorbidity was 5.9% among Asian, 17.4% among Black, 10.7% among Latino/Hispanic, and 13.5% among White individuals. Prevalence increased for all racial/ethnic groups during the study period (P<0.005 for each), with no significant change in the differences between them. In 2018, when compared with White people, multimorbidity was more prevalent among Black individuals (+2.5 percent points [95% CI: +0.5, +4.6]) and less prevalent among Asian and Latino individuals (-6.6 points [-8.8, -4.4] and -2.1 points [-4.0, -0.2], respectively). The estimated prevalence of reporting at least 1, 2, 3, or 4 conditions all increased with age across all groups, with Black individuals having the greatest prevalence in each age category. Among those aged [≥]30 years, Black people had multimorbidity rates equivalent to those of Latino/Hispanic and White people aged 5 years older, and Asian people aged 10 years older. Notably, the prevalence of multimorbidity diverged between Black people and White people among those aged 30 years, reached its maximum difference of 10.1 percentage points (95% CI: 8.2, 12.1) among those aged 60, and converged to reach similar rates among those aged [≥]80.

ConclusionsFrom 1999 to 2018, a period of increasing multimorbidity prevalence for all the groups studied, there has not been any significant progress in eliminating disparities between Black and White people. The disparity began among young adults. Public health interventions that prevent the onset of chronic conditions in early life may be needed to eliminate these disparities.


sentences:
Democratic governance and excess mortality during the COVID-19 pandemic BackgroundExcess mortality has been used to assess the health impact of COVID-19 across countries. Democracies aim to build trust in government and enable checks and balances on decision-making, which may be useful in a pandemic. On the other hand, democratic governments have been criticised as slow to enforce restrictive policies and being overly influenced by public opinion. This study sought to understand whether strength of democratic governance is associated with the variation in excess mortality observed across countries during the pandemic.

MethodsThrough linking open-access datasets we constructed univariable and multivariable linear regression models investigating the association between country EIU Democracy Index (representing strength of democratic governance on a scale of 0 to 10) and excess mortality rates, from February 2020 to May 2021. We stratified our analysis into high-income and low and middle-income country groups and adjusted for several important confounders.

ResultsAcross 78 countries, the mean EIU democracy index was 6.74 (range 1.94 to 9.81) and the mean excess mortality rate was 128 per 100,000 (range -55 to 503 per 100,000). A one-point increase in EIU Democracy Index was associated with a decrease in excess mortality of 26.3 per 100,000 (p=0.002), after accounting for COVID-19 cases, age [≥] 65, gender, prevalence of cardiovascular disease, universal health coverage and the strength of early government restrictions. This association was particularly strong in high-income countries ({beta} -47.5, p<0.001) but non-significant in low and middle-income countries ({beta} -10.8, p=0.40).

ConclusionsSocio-political factors related to the way societies are governed have played an important role in mitigating the overall health impact of COVID-19. Given the omission of such considerations from outbreak risk assessment tools, and their particular significance in high-income countries rated most highly by such tools, this study strengthens the case to broaden the scope of traditional pandemic risk assessment.

Key MessagesO_ST_ABSWhat is already known?C_ST_ABSO_LIPrevious studies have found that as countries become more democratic they experience a decline in rates of infant and child mortality, infections such as tuberculosis, and non-communicable diseases.
C_LIO_LIIn Europe, more democratic countries were initially more reluctant to adopt restrictive COVID-19 measures that could conflict with democratic principles, including lockdowns.
C_LI

What are the new findings?O_LIWe found that a one-point increase in EIU Democracy Index was associated with a decrease in excess mortality of 26.3 per 100,000 (p=0.002), after accounting for several confounders including demographics, numbers of cases and the strength of early government responses.
C_LIO_LIThis association was particularly significant in high-income countries ({beta} - 47.5, p<0.001), suggesting that way societies are governed has played an important role in mitigating the impact of COVID-19.
C_LI

What do the new findings imply?O_LIGiven the omission of social, political and cultural considerations from outbreak risk assessment tools, and criticisms of such tools that have failed to accurately reflect the observed impact of the pandemic across high-income countries, this study builds on the case to broaden of the scope of traditional pandemic risk assessment.
C_LIO_LIFuture research into the mechanisms underlying our findings will help to understand and address the complex and deep-rooted vulnerabilities countries face in a protracted and large-scale public health emergency.
C_LI


sentences: A computational optimization approach for the automatic generation of Gamma Knife radiosurgery treatment plans Gamma Knife (GK) radiosurgery is a non-invasive treatment modality which allows single fraction delivery of focused radiation to one or more brain targets. Treatment planning mostly involves manual placement and shaping of shots to conform the prescribed dose to a surgical target. This process can be time consuming and labour intensive. An automated method is needed to determine the optimum combination of treatment parameters to decrease planning time and chance for operator-related error. Recent advancements in hardware platforms which employ parallel computational methods with stochastic optimization schemes are well suited to solving such combinatorial optimization problems efficiently. We present a method of generating optimized GK radiosurgery treatment plans using these techniques, which we name ROCKET (Radiosurgical Optimization Configuration Kit for Enhanced Treatments). Our approach consists of two phases in which shot isocenter positions are generated based on target geometry, followed by optimization of sector collimator parameters. Using this method, complex treatment plans can be generated, on average, in less than one minute, a substantial decrease relative to manual planning. Our results also demonstrate improved selectivity and treatment safety through decreased exposure to nearby organs-at-risk (OARs), compared to manual reference plans with matched coverage. Stochastic optimization is therefore shown to be a robust and efficient clinical tool for the automatic generation of GK radiosurgery treatment plans.

labels: radiology and imaging


sentences:
Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous?-A retrospective cohort study BackgroundHypoxia in patients with COVID-19 is one of the strongest predictors of mortality. Silent hypoxia is characterized by the presence of hypoxia without dyspnea.. Silent hypoxia has been shown to affect the outcomes in previous studies.

Research QuestionAre the outcomes in patients presenting with silent hypoxia different from those presenting with dyspneic hypoxia?

Study design and MethodsThis was a retrospective study of a cohort of patients with SARS-CoV-2 infection who were hypoxic at presentation. Clinical, laboratory, and treatment parameters in patients with silent hypoxia and dyspneic hypoxia were compared. Multivariate logistic regression models were fitted to identify the factors predicting mortality.

ResultsAmong 2080 patients with COVID-19 admitted to our hospital, 811 patients were hypoxic with SpO2<94% at the time of presentation. 174 (21.45%) did not have dyspnea since the onset of COVID-19 symptoms. 5.2% of patients were completely asymptomatic for COVID-19 and were found to be hypoxic only on pulse oximetry. The case fatality rate in patients with silent hypoxia was 45.4% as compared to 40.03% in dyspneic hypoxic patients (P=0.202). The odds ratio of death was 1.1 (95% CI 0.41-2.97) in the patients with silent hypoxia after adjusting for baseline characteristics, laboratory parameters, treatment, and in-hospital complications, which did not reach statistical significance (P=0.851).

InterpretationSilent hypoxia may be the only presenting feature of COVID-19. Since the case fatality rate is comparable between silent and dyspneic hypoxia, it should be recognized early and treated as aggressively. Since home isolation is recommended in patients with COVID-19, it is essential to use pulse oximetry at the home setting to identify these patients.

labels: respiratory medicine


sentences:
Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cells B cell depletion using rituximab is widely used to treat autoimmune diseases, but patient response varies. The efficacy of rituximab is limited by the efficiency of depletion. Strategies to improve response include altering rituximab dosing, switching anti-CD20-mAb, alternative B cell targets, or non-B cell targeted therapies. Implementing an appropriate strategy requires understanding of the mechanism(s) of resistance to depletion and, if this varies between individuals, a means to test for it. Rituximab kills B cells via a variety of Fc{gamma} receptor (Fc{gamma}R)-dependent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), as well as non-Fc{gamma}R mechanisms. We conducted a longitudinal cohort study in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) using two national registries. Qualitative and quantitative FCGR functional variants were measured using multiplexed ligation-dependent probe amplification, supplemented by novel FCGR2C assays.

We provide consistent evidence that FCGR3A, specifically increased number of copies of the FCGR3A-158V allele, was the major Fc{gamma}R gene associated with rituximab response, including clinical response in RA and SLE and depth of B cell depletion in the combined cohort. In SLE, we provide preliminary data suggesting increased FCGR2C ORF copies were also associated with improved clinical response. Furthermore, we demonstrated the impact of disease status and concomitant therapies on both natural killer cell Fc{gamma}RIIIa expression and rituximab-induced ADCC; demonstrating increased Fc{gamma}RIIIa expression and FCGR3A genotype were independently associated with clinical response and B cell depletion. Our findings highlight the importance of enhancing Fc{gamma}R-effector functions, may help stratify patients, and support ongoing development of next-generation CD20 depleting therapeutics.

One Sentence SummaryThe high affinity Fc{gamma}RIIIa allotype on NK cells explains depth of B cell depletion and clinical response in rituximab therapy for autoimmune disease

labels: rheumatology


sentences:
What medical students think about measurement of their wellbeing and the implications for pastoral support: cross sectional survey and qualitative interviews ObjectivesTo find out how, why and when medical students think wellbeing should be measured.

DesignA mixed methods study comprising a cross-sectional online survey (November 2020-March 2021) and semi-structured on-line interviews. Views on the frequency of availability for measurement, the format, type and purpose of measurement, and with whom wellbeing should be discussed were measured. When an outcome was scored 7-9 on a 9-point Likert scale of agreement by [≥]75% of participants it was considered critical, in line with COMET and GRADE processes for rating recommendations. Inductive thematic analysis was undertaken on the interview transcripts by two independent researchers.

SettingAll Medicine programmes at University of Southampton.

ParticipantsMedical students from all years took part in the survey (n=118) and interviews (n=16).

ResultsParticipant demographics were similar to national medical student demographics. Most participants (94%) felt able to give 5 minutes to measure their wellbeing at least once a month. No single format of measurement was rated critical. Research, governance and individual feedback all reached the 75% threshold for the purpose being considered critically important. Only subjective assessments undertaken by the individual in real-time were rated as critically important (78.1%) measurement tools. Students selected that they would discuss their wellbeing with other medical students (n=87) nearly as often as they selected a member of the Faculty (n=104). Top determinants of wellbeing picked by medical students were energy, ability to do activities of daily living, and negative feelings. Five interview themes further explained these findings.

ConclusionsFive recommendations about self-care teaching, quality-assured pastoral and peer support, proactive wellbeing check-ins and demographic data are discussed in light of these findings. Methods to achieve them are suggested, which are medical student-centred, and which make use of existing resources.

Strengths and limitations of this studyO_LIThis study provides new information on how, why and when medical students think their wellbeing should be measured.
C_LIO_LIA mixed methods approach allowed the reasons behind the survey answers to be captured in ensuing interviews.
C_LIO_LIUsing the [≥]75% a prior cut off for critical importance from COMET and GRADE allowed evidence-based recommendations for wellbeing measurement for medical students.
C_LIO_LIIt was not possible to recruit the number of students needed to make national inferences, although participant demographics were similar to national medical student demographics.
C_LIO_LIA national cross-sectional survey would provide further evidence for medical schools in devising wellbeing provisions.
C_LI

labels: medical education


sentences:
Effectiveness of a novel non-intrusive continuous-use air decontamination technology to reduce microbial contamination in clinical settings: A multi-centric study BackgroundDespite rigorous disinfection, fumigation and air treatment, infectious microbial load has been found to circulate and survive for significant durations in health care settings. This raises significant concerns for hospital acquired infections. We have developed a novel, hybrid, trap- and-kill airborne-microbicidal technology called "ZeBox" which is efficient in clearing 99.999% of airborne microbial load under controlled lab conditions. In this study we evaluate the clinical performance of the ZeBox in reducing airborne and surface microbial load in two independent hospital settings.

MethodsThe studies were conducted in single bed and multi bed ICU of two hospitals. Airborne and surface microbial loads were collected at pre-determined sampling sites pre- and post-deployment of the ZeBox enabled device. The Normality of data distribution was determined using the Shapiro-Wilk test. Statistical significance was determined using Students T test and Mann-Whitneys U test. Pathogenic and opportunistic organisms were characterized using 16S rDNA sequencing. Furthermore, the antibiotic sensitivity of the isolated organisms was tested against current treatments of choice across major antibiotic classes.

ResultsPost-deployment, we found statistically significant reductions in both airborne and surface microbial load within the operating range of the ZeBox enabled technology. Across the both hospital ICUs, there was 90% reduction of airborne microbial load on average, and 75% reduction of surface microbial load on average, providing a low bioburden zone of roughly 10-15 feet diameter around the unit. These reduced microbial levels were maintained during the entire duration of device operation over several weeks. Many of the clinical isolates recovered from one of the hospitals were drug resistant, which highlighted the potential ability of ZeBox to eliminate drug-resistant microbes and thereby reduce the frequency of hospital acquired infections.

ConclusionsZeBox enabled technology can significantly reduce a broad spectrum of microbial burden in air and on surfaces in clinical settings. It can thereby serve an unmet need in reducing the incidence of hospital acquired infections.

labels: occupational and environmental health


sentences:
Predicted long-term impact of COVID-19 pandemic-related care delays on cancer incidence and mortality in Canada ObjectivesThe COVID-19 pandemic has affected cancer care worldwide. This study aimed to estimate the long-term impacts of the pandemic on cancer incidence and mortality in Canada using a mathematical model.

MethodsWe developed a stochastic microsimulation model to estimate the cancer care disruptions and its long-term impact on cancer incidence and mortality in Canada. The model reproduces cancer incidence, survival, and epidemiology in Canada, by using cancer incidence, stage at diagnosis and survival data from the Canadian Cancer Registries. We modeled reported declines in cancer diagnoses and treatments recorded in provincial administrative datasets from March 2020-June 2021. We assumed that diagnostic and treatment delays lead to an increased rate of death. Based on the literature, we assumed each 4-week delay in diagnosis and treatment would lead to a 6% to 50% higher rate of cancer death. Results are the median predictions of 10 stochastic simulations.

FindingsThe model predicts that cancer care disruptions during the COVID-19 pandemic could lead to 21,247 (2{middle dot}0%) more cancer deaths in Canada in 2020-2030, assuming treatment capacity is recovered to 2019 pre-pandemic levels in 2021. This represents 355,172 life years lost expected due to pandemic-related diagnostic and treatment delays. The highest absolute expected excess cancer mortality was predicted in breast, lung, and colorectal cancers, and in the provinces of Ontario, Quebec, and British Columbia. Diagnostic and treatment capacity in 2021 onwards highly influenced the number of predicted cancer deaths over the next decade.

InterpretationCancer care disruptions during the Covid-19 pandemic could lead to significant life loss; however, most of these could be mitigated by increasing diagnostic and treatment capacity in the post-pandemic era to address the service backlog.

FundingCanadian Institutes of Health Research

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe performed a review of modeling studies predicting the impact of pandemic-induced disruptions to cancer care on cancer survival outcomes. We searched MEDLINE on 2 July 2021 for records published from 1 January 2020 with no language restrictions. Our search consisted of index keywords [Cancer AND COVID-19 AND [(delay AND diagnosis) OR (delay AND screening) OR (delay AND treatment)] AND outcomes AND modelling study]. We identified 14 studies that model the long-term effect of disruptions to cancer screening programs, diagnostic intervals, and to treatment intervals for common cancers. Most studies (9/14) assessed the impact of cancer screening disruptions but did not assume any treatment disruptions. Disruptions to cancer screening services in high income health systems were estimated to lead to small increases in cancer incidence and mortality, even with immediate resumption of screening to services after disruption periods. Fewer studies examined the impact of diagnostic referral and treatment disruptions; these are similarly predicted to lead to increases in cancer incidence and mortality, with varying impacts depending on cancer site. Due to difficulties in obtaining real-time healthcare data, previous studies have relied on assumptions regarding the duration of health care disruptions (1-, 3-, 6-, 12-, to 24-months) rather than on empirical data. All studies restricted their analysis to the impact on a single or a few cancer sites.

Added value of this studyOur stochastic microsimulation model is the first to assess the population-level impact of diagnostic and treatment disruptions on overall cancer mortality across all sites. Using Canadian cancer statistics and expert validation of treatment modalities, we constructed a model that reproduced pre-pandemic cancer mortality data. An important added value of this analysis compared to previous studies was that we were able to integrate empirical data on cancer-related procedures during the pandemic era to model disruptions to cancer care.

Implications of all the available evidenceWe estimate there could be a 2{middle dot}0% increase over expected cancer mortality between 2020-2030 in Canada due to pandemic-related disruptions to diagnostic and treatment intervals. Our results identified that a 10-20% increase in cancer care service capacity over pre-pandemic levels could prevent a considerable amount of the predicted excess cancer-related deaths by reducing diagnostic and treatment backlogs. By stratifying our reported outcomes by sex, age, province, and cancer site, we provide a long-term perspective that can inform post-pandemic public health policy or aid in prioritization of patients in the event of a resurgence of COVID-19. While our model is specific to Canada, it could be applied to countries that have experienced comparable COVID-19-related healthcare disruptions.

labels: oncology


sentences:
Estimating the global demand curve for a leishmaniasis vaccine: a generalisable approach based on global burden of disease estimates BackgroundA pressing need exists to develop vaccines for neglected diseases, including leishmaniasis. However, the development of new vaccines is dependent on their value to two key players - vaccine developers and manufacturers who need to have confidence in the global demand in order to commit to research and production; and governments (or other international funders) who need to signal demand based on the potential public health benefits of the vaccine in their local context, as well as its affordability. A detailed global epidemiological analysis is rarely available before a vaccine enters a market due to lack of resources as well as insufficient global data necessary for such an analysis. Our study seeks to bridge this information gap by providing a generalisable approach to estimating the commercial and public health value of a vaccine in development relying primarily on publicly available Global Burden of Disease (GBD) data. This simplified approach is easily replicable and can be used to guide discussions and investments into vaccines and other health technologies where evidence constraints exist. The approach is demonstrated through the estimation of the demand curve for a future leishmaniasis vaccine.

Methodology/Principal findingsWe project the ability to pay over the period 2030-2040 for a vaccine preventing cutaneous and visceral leishmaniasis (CL / VL), using an illustrative set of countries which account for most of the global disease burden. First, based on previous work on vaccine demand projections in these countries and CL / VL GBD-reported incidence rates, we project the potential long-term impact of the vaccine on disability-adjusted life years (DALYs) averted as a result of reduced incidence. Then, we apply an economic framework to our estimates to determine vaccine affordability based on the abilities to pay of governments and global funders, leading to estimates of the demand and market size. Based on our estimates, the maximum ability-to-pay of a leishmaniasis vaccine (per course, including delivery costs), given the current estimates of incidence and population at risk, is higher than $5 for nearly half of the 24 countries considered, with a median value-based maximum price of $4.4-$5.3, and total demand of over 560 million courses.

Conclusion/SignificanceOur results demonstrate that both the quantity of vaccines estimated to be required by the countries considered as well as their ability-to-pay could make a vaccine for leishmaniasis commercially attractive to potential manufacturers. The methodology used can be equally applied to other technology developments targeting health in developing countries.

Author summaryAs of 2019, between 498,000 and 862,000 new cases of all forms of leishmaniasis were estimated to occur each year resulting in up to 18,700 deaths and up to 1.6 million DALYs lost. Given low treatment coverage, poor compliance and the emergence of drug resistance, challenges in sustaining vector control strategies and the ability of parasites to persist in animal reservoirs independent of human infection, an effective vaccine could significantly reduce the health and economic burden of these diseases. However, commitment to the development of a new vaccine requires a market signal from governments and global funders who in turn require better estimates of the potential public health value of the vaccine. This study uses the development of a leishmaniasis vaccine as a case study to illustrate a generalizable approach to estimating the commercial and public health value of a technology relying primarily on publicly available GBD data. More specifically, by projecting the potential public health impact of the rollout of a leishmaniasis vaccine and translating this into monetary values based on the concept of health opportunity cost, we estimate the demand curve for such a vaccine for an 11-year period between 2030 and 2040. At an estimated global demand of over 560 million courses and a median value-based maximum price of $4.4-$5.3, our results demonstrate that both the quantity of vaccines estimated to be required by the countries considered as well as their ability-to-pay make the vaccine commercially attractive to potential manufacturers.

labels: health economics


sentences: When do we need massive computations to perform detailed COVID-19 simulations? The COVID-19 pandemic has infected over 200 million people worldwide and killed more than 4 million as of August 2021. Many intervention strategies have been utilized by governments around the world, including masks, social distancing, and vaccinations. However, officials making decisions regarding interventions may have a limited time to act. Computer simulations can aid them by predicting future disease outcomes, but they also have limitations due to requirements on processing power or time. This paper examines whether a machine learning model can be trained on a small subset of simulation runs to inexpensively predict future disease trajectories very close to the original simulation results. Using four previously published agent-based models for COVID-19, this paper analyzes the predictions of decision tree regression machine learning models and compares them to the results of the original simulations. The results indicate that accurate machine learning meta-models can be generated from simulation models with no strong interventions (e.g., vaccines, lockdowns) using small amounts of simulation data. However, meta-models for simulation models that include strong interventions required much more training data to achieve a similar accuracy. This indicates that machine learning meta-models could be used in some scenarios to assist in faster decision making.


sentences:
Community-Based Culturally Tailored Education Programs for Black Adults with Cardiovascular Disease, Diabetes, Hypertension, and Stroke: A Systematic Review Protocol BackgroundChronic conditions and stroke disproportionately affect Black adults in communities all around the world due patterns of systemic racism, disparities in care, and lack of resources. To address unequal care received by Black communities, a shift to community-based programs that deliver culturally-tailored programs to meet the needs of the communities they serve, including Black adults who tend to have reduced access to postacute services, may give an alternative to a healthcare model which reinforces health inequities. However, community-based culturally-tailored programs (CBCT) are relatively understudied but show promise to improve the delivery of services to marginalized communities. The objectives of this review are to: (i) determine key program characteristics and outcomes of CBCT programs that are designed to improve health outcomes in Black adults with cardiovascular disease, hypertension, diabetes, or stroke and (ii) identify which of the five categories of culturally appropriate programs from Kreuter and colleagues have been used to implement CBCT programs.

MethodsThis is a protocol for a systematic review that will search MEDLINE, EMBASE, and CINAHL databases to identify community-based culturally-tailored programs for Black adults with cardiovascular disease, hypertension, diabetes, or stroke.

DiscussionHealth inequities have disproportionately impacted Black communities and will continue to persist if adjustments are not prioritized within healthcare to provide services, care, and programs meant to address the specific barriers to better health experienced. Many interventions meant to improve the health outcomes of marginalized groups are created with little input from target communities, leading to interventions that may not address the specific barriers contributing to poor health outcomes and are designed and implemented from an outsiders perspective. The inclusion of community members allows for a deeper understanding of the issues facing the community and provides an opportunity to incorporate cultural values to potentially increase the efficacy, tailoring the intervention to distinct communities. An alternative to current healthcare interventions must be explored to reduce the health gap experienced by Black adults.

Trial registrationPROSPERO CRD42021245772

labels: health systems and quality improvement


sentences:
A Learning Health System Approach to the COVID-19 Pandemic: System-Wide Changes in Clinical Practice and 30-Day Mortality Among Hospitalized Patients IntroductionRapid, continuous implementation of credible scientific findings and regulatory approvals is often slow in large, diverse health systems. The COVID-19 pandemic created a new threat to this common "slow to learn and adapt" model in healthcare. We describe how UPMC committed to a rapid learning health system (LHS) model to respond to the COVID-19 pandemic.

MethodsAn observational cohort study was conducted among 11,429 hospitalized patients from 22 hospitals (PA, NY) with a primary diagnosis of COVID-19 infection (March 19, 2020 - June 6, 2021). Sociodemographic and clinical data were captured from UPMC electronic medical record (EMR) systems. Patients were grouped into four time-defined patient "waves" based on nadir of daily hospital admissions, with wave 3 (September 20, 2020 - March 10, 2021) split at its zenith due to high volume with steep acceleration and deceleration. Outcomes included changes in clinical practice (e.g., use of corticosteroids, antivirals, and other therapies) in relation to timing of internal system analyses, scientific publications, and regulatory approvals, along with 30-day rate of mortality over time.

ResultsMean (SD) daily number of hospital admissions was 26 (28) with a maximum 7-day moving average of 107 patients. System-wide implementation of the use of dexamethasone, remdesivir, and tocilizumab occurred within days of release of corresponding seminal publications and regulatory actions. After adjustment for differences in patient clinical profiles over time, each month of hospital admission was associated with an estimated 5% lower odds of 30-day mortality (adjusted OR = 0.95, 95% confidence interval: 0.92 - 0.97, p < .001).

ConclusionsIn our large LHS, near real-time changes in clinical management of COVID-19 patients happened promptly as scientific publications and regulatory approvals occurred throughout the pandemic. Alongside these changes, patients with COVID-19 experienced lower adjusted 30-day mortality following hospital admission over time.


sentences:
How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from Zambia IntroductionAttrition from HIV treatment is high during patients first 6 months after antiretroviral therapy (ART) initiation and patients with less than 6 months on ART are systematically excluded from most differentiated service delivery (DSD) models, which are intended to reduce attrition. Despite eligibility criteria requiring greater than 6 months on ART, some patients enroll earlier. Using routinely-collected medical record data in Zambia, we compared loss to follow-up (LTFU) among patients enrolling in DSD models early (<6 months on ART) to LTFU among those who enrolled according to guidelines ([≥]6 months on ART) in order to assess whether the ART experience eligibility criterion is necessary.

MethodsWe extracted data from electronic medical records for adults ([≥]15 years) who initiated ART between 01/01/2019 and 31/12/2019 and evaluated LTFU, defined as >90 days late for last scheduled medication pickup, at 18 months for "early enrollers" (DSD enrolment after <6 months on ART) and "established enrollers" (DSD enrolment after [≥]6 months on ART). We used a log-binomial model to compare LTFU risk between groups, adjusting for age, sex, urban/rural status, ART refill interval and DSD model.

ResultsFor 6,340 early enrollers and 25,857 established enrollers there were no important differences between the groups in sex (61% female), age (median 37 years), or setting (65% urban). ART refill intervals were longer for established vs early enrollers (72% vs 55% were given 4-6-month refills). LTFU at 18 months was 3% (192/6,340) for early enrollers and 5% (24,646/25,857) for established enrollers. Early enrollers were 41% less likely to be LTFU than established patients (adjusted risk ratio [95% confidence interval] 0.59 [0.50-0.68]).

ConclusionsPatients enrolled in DSD models in Zambia with < 6 months on ART were more likely to be retained in care than patients referred after they were established on ART. A limitation of the analysis is that early enrollers may have been selected for DSD participation due to providers and patients expectations about future retention. Offering DSD model entry to at least some ART patients <6 months after ART initiation may help address high attrition during the early treatment period.

labels: hiv aids


sentences: Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals Surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires tests to monitor antibody formation and prevalence. We detected SARS-CoV-2 antibodies using red cells coated by Kode technology with short peptides derived from the SARS-CoV-2 spike protein. Such modified red cells, called C19-kodecytes, can be used as reagent cells in any manual or automated column agglutination assay. We investigated the presence of SARS-CoV-2 antibodies in 130 samples from COVID-19 convalescent plasma donors using standard manual technique, two FDA authorized ELISA assays and a virus neutralisation assay. The sensitivity of the C19-kodecyte assay was 88%, comparable to the anti-SP and anti-NCP ELISAs (86% and 83%) and the virus neutralisation assay (88%). The specificity of the C19-kodecyte assay was 90% (anti-SP 100% and anti-NCP 97%). Likewise, 231 samples from 73 vaccinated individuals were tested with an automated analyser and we monitored the appearance and persistence of SARS-CoV-2 antibodies. The C19-kodecyte assay is a robust tool for SARS-CoV-2 antibody detection. Automated blood group analyser use enables large-scale SARS-CoV-2 antibody testing for vaccination monitoring in population surveys.

labels: infectious diseases


sentences:
Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial BackgroundSARS-CoV-2 viral entry may disrupt angiotensin II (Ang II) homeostasis in part via ACE2 downregulation, potentially contributing to COVID-19 induced lung injury. Preclinical models of viral pneumonias that utilize ACE2 demonstrate Ang II type 1 receptor (AT1R) blockade mitigates lung injury, though observational COVID-19 data addressing the effect of AT1R blockade remain mixed.

MethodsMulticenter, blinded, placebo-controlled randomized trial of losartan (50 mg PO twice daily for 10 days) versus placebo. Hospitalized patients with COVID-19 and a respiratory sequential organ failure assessment score of at least 1 and not already taking a renin-angiotensin-aldosterone system (RAAS) inhibitor were eligible. The primary outcome was the imputed partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio at 7 days. Secondary outcomes included ordinal COVID-19 severity, oxygen, ventilator, and vasopressor-free days, and mortality. Losartan pharmacokinetics (PK) and RAAS components [Ang II, angiotensin-(1-7) (Ang-(1-7)), ACE, ACE2] were measured in a subgroup of participants.

FindingsFrom April 2020 - February 2021, 205 participants were randomized, 101 to losartan and 104 to placebo. Compared to placebo, losartan did not significantly affect PaO2/FiO2 ratio at 7 days [difference of -24.8 (95% -55.6 to 6.1; p=0.12)]. Losartan did not improve any secondary clinical outcome, but worsened vasopressor-free days. PK data were consistent with appropriate steady-state concentrations, but we observed no significant effect of losartan on RAAS components.

InterpretationInitiation of orally administered losartan to hospitalized patients with COVID-19 and acute lung injury does not improve PaO2 / FiO2 ratio at 7 days. These data may have implications for ongoing clinical trials.

Trial RegistrationLosartan for Patients With COVID-19 Requiring Hospitalization (NCT04312009), https://clinicaltrials.gov/ct2/show/NCT04312009


sentences:
Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021 ObjectiveLarge clinical trials have proved the efficacy of Covid-19 vaccine, and the number of literature about the effectiveness is rapidly growing in the first half of year after mass vaccination was administrated globally. This rapid review aims to provide evidence syntheses as a means to complement the current evidence on the vaccine effectiveness (VE) against various outcomes in real-world settings.

MethodsThis review is conducted based on the updated guideline of PRISMA 2020. Databases (PubMed, EMBASE, and MedRxiv) were searched up to 30 June 2021, (PROSPERO ID: 266866). The studies that assessed the VE of the 6 WHO-authorized vaccines (BNT162b2, ChAdOx1, Ad26.COV2.S, mRNA-1273, BBIBP-CorV, and CoronaVac) were eligible to be included. Quality assessment was performed based on ROBINS-I by 2 independent reviewers.

FindingsA total of 39 studies were included, covering over 15 million of participants from 11 nations. Among the general population after 2 doses of vaccination, the VE against symptomatic SARS-CoV-2 infection was estimated at 89%-97%, 92% (95% CI, 78%-97%) and 94% (95% CI, 86%-97%) for BNT162b2, ChAdOx1 and mRNA-1273, respectively. As for the protective effects against B.1.617.2 related symptomatic infection, the VE was 88% (95% CI, 85.3%-90.1%) by BNT162b2 and 67.0% (95% CI, 61.3%-71.8%) by ChAdOx1 after fully vaccination.

ConclusionThis review revealed a consistently high effectiveness of vaccines among the general population in real-world settings. Further studies are needed to provide the information on different races/ethnicity, the effects against SARS-CoV-2 variants, and the duration of protection with longer study time.


sentences:
Balanced crystalloids compared to normal saline for fluid therapy in critically ill adult patients: Systematic review and meta-analysis protocol IntroductionThe choice of intravenous fluid for fluid therapy in critically ill adult patients remains a matter of debate. Currently, crystalloids are used more often than colloids, with ongoing controversy over the relative efficacy and safety of buffered salt solutions (BSS) versus normal saline (0.9% sodium chloride). In 2021 two large pragmatic trials enrolling critically ill patients will add substantial new data to address this controversy. We will conduct a systematic review and meta-analysis of randomised controlled trials (RCTs) that will include the data from these two trials to provide clinicians with the most up to date evidence and robust evidence to guide their choice of crystalloid fluids.

Methods and analysisWe will include RCTs that compare the effect of buffered salt solutions to normal saline for fluid resuscitation and/or fluid therapy in critically ill adults, on all-cause mortality and other patient centred outcomes. We will perform a search that includes the electronic databases MEDLINE and EMBASE, and clinical trial registries. Two reviewers will independently screen titles and abstracts, perform full article reviews and extract study data, with discrepancies resolved by a third reviewer. We will report study characteristics and assess risk of bias using the Cochrane Risk-of-Bias tool. We will perform Hartung-Knapp-Sidik-Jonkman random-effects aggregate data meta-analysis whenever it is feasible to do so. We will evaluate overall certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

Ethics and disseminationThis systematic review and meta-analysis does not require ethical approval as it does not involve primary data collection. We will publish our results in a peer-reviewed scientific journal and present them at national and international scientific conferences.

PROSPERO registration numberCRD42021243399

Strengths and limitations of this review [box]This systematic review will provide up-to-date evidence to answer the focused clinical question: In adult patients who are critically ill, does administering balanced crystalloid solutions for fluid therapy reduce mortality and other patient-centered outcomes, compared with administering 0.9% sodium chloride?

We will conduct a systematic review according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines, searching three electronic databases, clinical trial registries and published conference abstracts, with two independent reviewers evaluating studies and extracting data.

A meta-analysis will assess the primary outcome of all-cause mortality at 90 days and secondary outcomes of ventilator and vasopressor free days, renal replacement therapy use, incidence of acute kidney injury, and patient quality of life outcomes.

The limitations of this review include the clinical heterogeneity of the included trials, diversity of the targeted population receiving fluid therapy, variability in the composition of balanced crystalloid solutions, and timing of initiation of study crystalloids. We will address all limitations with the Grading of Recommendations, Assessment, Development and Evaluations framework.

labels: intensive care and critical care medicine


sentences:
Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells. The IKAROS family transcription factors regulate lymphocyte development. Loss-of-function variants in IKZF1 cause primary immunodeficiency, but IKAROS family members IKZF2 and IKZF3 have not yet been associated with immunodeficiency yet. Here, we describe a pedigree with a heterozygous truncating variant in IKZF2, encoding the translational activator and repressor HELIOS which is highly expressed in regulatory T cells and effector T cells, particularly of the CD8+ T cell lineage. Protein-protein interaction analysis revealed that the variant abolished HELIOS dimerizations as well as binding to members of the Mi-2/NuRD chromatin remodeling complex. Patients carrying the IKZF2 variant presented with a combined immunodeficiency phenotype characterized by recurrent upper respiratory infections, thrush and mucosal ulcers, as well as chronic lymphadenopathy. With extensive immunophenotyping, functional assays, and transcriptional analysis we show that reduced HELIOS expression was associated with chronic T cell activation and increased production of pro-inflammatory cytokines both in effector and regulatory T cells. Lymph node histology from patients indicated dysregulated germinal center reactions. Moreover, affected individuals displayed profoundly reduced circulating MAIT cell numbers. In summary, we show that this novel loss-of-function variant in HELIOS leads to an immunodeficiency with signs of immune overactivation.

One sentence summaryTruncating variant of HELIOS causes immunodeficiency with signs of immune overactivation.

labels: allergy and immunology


sentences:
Causal and Associational Linking Language From Observational Research and Health Evaluation Literature in Practice: A systematic language evaluation We estimated the degree to which language used in the high profile medical/public health/epidemiology literature implied causality using language linking exposures to outcomes and action recommendations; examined disconnects between language and recommendations; identified the most common linking phrases; and estimated how strongly linking phrases imply causality.

We searched and screened for 1,170 articles from 18 high-profile journals (65 per journal) published from 2010-2019. Based on written framing and systematic guidance, three reviewers rated the degree of causality implied in abstracts and full text for exposure/outcome linking language and action recommendations.

Reviewers rated the causal implication of exposure/outcome linking language as None (no causal implication) in 13.8%, Weak 34.2%, Moderate 33.2%, and Strong 18.7% of abstracts. The implied causality of action recommendations was higher than the implied causality of linking sentences for 44.5% or commensurate for 40.3% of articles. The most common linking word in abstracts was "associate" (45.7%). Reviewers ratings of linking word roots were highly heterogeneous; over half of reviewers rated "association" as having at least some causal implication.

This research undercuts the assumption that avoiding "causal" words leads to clarity of interpretation in medical research.

labels: epidemiology


sentences:
Mental health and substance use associated with hospitalization among people with laboratory confirmed diagnosis of COVID-19 in British Columbia: a population-based cohort study BackgroundThis study identified factors associated with hospital admission among people with laboratory-diagnosed COVID-19 cases in British Columbia.

MethodsThis study was performed using the BC COVID-19 Cohort, which integrates data on all COVID-19 cases, hospitalizations, medical visits, emergency room visits, prescription drugs, chronic conditions and deaths. The analysis included all laboratory-diagnosed COVID-19 cases in British Columbia as of January 15th, 2021. We evaluated factors associated with hospital admission using multivariable Poisson regression analysis with robust error variance.

FindingsFrom 56,874 COVID-19 cases included in the analyses, 2,298 were hospitalized. Models showed significant association of the following factors with increased hospitalization risk: male sex (adjusted risk ratio (aRR)=1.27; 95%CI=1.17-1.37), older age (p-trend <0.0001 across age groups with a graded increase in hospitalization risk with increasing age [aRR 30-39 years=3.06; 95%CI=2.32-4.03, to aRR 80+years=43.68; 95%CI=33.41-57.10 compared to 20-29 years-old]), asthma (aRR=1.15; 95%CI=1.04-1.26), cancer (aRR=1.19; 95%CI=1.09-1.29), chronic kidney disease (aRR=1.32; 95%CI=1.19-1.47), diabetes (treated without insulin aRR=1.13; 95%CI=1.03-1.25, requiring insulin aRR=5.05; 95%CI=4.43-5.76), hypertension (aRR=1.19; 95%CI=1.08-1.31), injection drug use (aRR=2.51; 95%CI=2.14-2.95), intellectual and developmental disabilities (aRR=1.67; 95%CI=1.05-2.66), problematic alcohol use (aRR=1.63; 95%CI=1.43-1.85), immunosuppression (aRR=1.29; 95%CI=1.09-1.53), and schizophrenia and psychotic disorders (aRR=1.49; 95%CI=1.23-1.82). Among women of reproductive age, in addition to age and comorbidities, pregnancy (aRR=2.69; 95%CI=1.42-5.07) was associated with increased risk of hospital admission.

InterpretationOlder age, male sex, substance use, intellectual and developmental disability, chronic comorbidities, and pregnancy increase the risk of COVID-19-related hospitalization.

FundingBC Centre for Disease Control, Canadian Institutes of Health Research.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSFactors such as older age, social inequities and chronic health conditions have been associated to severe COVID-19 illness. Most of the evidence comes from studies that dont include all COVID-19 diagnoses in a jurisdiction), focusing on in-hospital mortality. In addition, mental illness and substance use were not evaluated in these studies. This study assessed factors associated with hospital admission among people with laboratory-diagnosed COVID-19 cases in British Columbia.

Added value of this studyIn this population-based cohort study that included 56,874 laboratory-confirmed COVID-19 cases, older age, male sex, injection drug use, problematic alcohol use, intellectual and developmental disability, schizophrenia and psychotic disorders, chronic comorbidities and pregnancy were associated with the risk of hospitalization. Insulin-dependent diabetes was associated with higher risk of hospitalization, especially in the subpopulation younger than 40 years. To the best of our knowledge this is the first study reporting this finding, (insulin use and increased risk of COVID-19-related death has been described previously).

Implications of all the available evidencePrioritization of vaccination in population groups with the above mentioned risk factors could reduce COVID-19 serious outcomes. The findings indicate the presence of the syndemic of substance use, mental illness and COVID-19, which deserve special public health considerations.


sentences:
Imputing cognitive impairment in SPARK, a large autism cohort BackgroundDiverse large cohorts are necessary for dissecting subtypes of autism, and intellectual disability is one of the most robust endophenotypes for analysis. However, current cognitive assessment methods are not feasible at scale.

MethodsWe developed five commonly used machine learning models to predict cognitive impairment (FSIQ<80 and FSIQ<70) and FSIQ scores among 521 children with autism using parent-reported online surveys in SPARK, and evaluated them in an independent set (n=1346) with a missing data rate up to 70%. We assessed accuracy, sensitivity and specificity by comparing predicted cognitive level against clinical IQ data.

ResultsThe elastic-net model has good performance (AUC=0.876, sensitivity=0.772, specificity=0.803) using 129 predictive features to impute cognitive impairment (FSIQ<80). Top ranked predictive features included parent-reported language and cognitive levels, age at autism diagnosis, and history of services. Prediction of FSIQ<70 and FSIQ scores also showed good prediction performance.

ConclusionsWe show cognitive levels can be imputed with high accuracy for children with autism, using commonly collected parent-reported data and standardized surveys. The current model offers a method for large scale autism studies seeking estimates of cognitive ability when standardized psychometric testing is not feasible.

Lay summaryChildren with autism who have more severe learning challenges or cognitive impairment have different needs that are important to consider in research studies. When children in our study were missing standardized cognitive testing scores, we were able to use machine learning with other information to correctly "guess" when they have cognitive impairment about 80% of the time. We can use this information in research in the future to develop more appropriate treatments for children with autism and cognitive impairment.

labels: psychiatry and clinical psychology


sentences:
History of suicide attempts and COVID-19 infection in Veterans with schizophrenia or schizoaffective disorder: effect modification by age and obesity ImportanceAs patients with schizophrenia or schizoaffective disorder have a high risk of suicide, and a history of suicide attempt is a strong predictor of suicide, determining whether history of suicide attempt is associated with COVID-19 in patients with schizophrenia or schizoaffective disorder has implications for suicide prevention in this patient population.

ObjectiveTo determine whether a history of suicide attempt is associated with COVID-19 in Veterans with schizophrenia or schizoaffective disorder.

DesignCross-sectional analyses of nation-wide electronic health records (EHR).

SettingUnited States Veterans Health Administration.

ParticipantsVeterans with a diagnosis of schizophrenia or schizoaffective disorder that received treatment at any United States Veterans Affairs Medical Center from January 1, 2020 to January 31, 2021.

ExposureHistory of suicide attempt.

Main OutcomeAdjusted and unadjusted odds ratios (ORs) for COVID-19 positivity in suicide attempters relative to non-attempters. Adjusted analyses included age, sex, race, marital status, BMI, and a medical comorbidity score.

ResultsA total of 101,032 Veterans [mean age 56.67 {+/-} 13.13 years; males 91,715 (90.8%)] were included in the analyses. There were 2,703 (2.7%) suicide attempters and 719 (0.7%) patients were positive for COVID-19. There was effect modification by age and BMI in the association of history of suicide attempt with COVID-19 positivity such that the association was only significant in obese (BMI [≥] 30) patients and patients younger than 59 years respectively. In the entire sample, the unadjusted OR for COVID-19 positivity in attempters was 1.42 (95% CI 0.97 to 2.10) and the adjusted odds ratio was 1.90 (95% CI 1.28 to 2.80). In patients younger than 59 years, and in the obese patients respectively, history of suicide attempt was associated with COVID-positive status in unadjusted analyses [OR 3.53 (95% CI 2.10 to 5.94); OR 2.22 (95% CI 1.29 to 3.81)] and adjusted analyses [OR 3.42 (95% CI 2.02 to 5.79); OR 2.85 (95% CI 1.65 to 4.94)].

Conclusions and RelevanceYoung or obese suicide attempters with a diagnosis of schizophrenia or schizoaffective disorders have higher rates of COVID-19 diagnosis; due to possible long-term neuropsychiatric sequelae of infection with SARS-CoV-2, such patients should be monitored closely.


sentences:
Socioeconomic and comorbid factors affecting mortality and length of stay in COVID-19 BackgroundThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic exposed and exacerbated health disparities between socioeconomic groups. Our purpose was to determine which disparities are most prevalent and their impact on length of stay (LoS) and in hospital mortality in patients diagnosed with Covid-19.

MethodsDe-Identified data for patients who tested positive for COVID-19 was abstracted from the HCA enterprise database. Data was binned into summary tables. A negative binomial regression with LoS as the dependent variable and a logistic regression of in-hospital mortality data, using age, insurance status, sex, comorbidities as the dependent variables, were performed.

ResultsFrom March 1, 2020 to August 23, 2020, of 111,849 covid testing patient records, excluding those with missing data (n=7), without confirmed COVID-19 (n=27,225), and those from a carceral environment (n=1,861), left 84,624 eligible patients. Compared to the US population, the covid cohort had more black patients (23.17% vs 13.4%). Compared to the white cohort, the black cohort had higher private insurance rates (28.52% vs. 23.68%), shorter LoS (IRR=0.97 CI=0.95-0.99, P<0.01) and lower adjusted mortality (OR 0.81, 95% CI 0.75-0.97). Increasing age was associated with increased mortality and LoS. Patients with Medicare or Medicaid had longer LoS (IRR=1.07, 95% CI=1.04-1.09) and higher adjusted mortality rates (OR=1.11, 95% CI=1-1.23) than those with private insurance

ConclusionConclusions We found that when blacks have higher rates of private insurance, they have shorter hospitalizations and lower mortality than whites, when diagnosed with Covid-19. Some other psychiatric and medical conditions also significantly impacted outcomes in patients with Covid-19.

Key PointsO_ST_ABSQuestionC_ST_ABSWhich social determinants of health and comorbidities are most prevalent and their impact on length of stay and in-hospital mortality in patients diagnosed with Covid-19?

FindingsIn this retrospective cohort of 84,624 with the black cohort having higher private insurance rates (28.52% vs. 23.68%), there was shorter LoS (IRR=0.97 CI=0.95-0.99, P<0.01) and lower adjusted mortality (OR 0.81, 95% CI 0.75-0.97). Age and several other medical and psychiatric comorbidities were also found to correlate with length of stay and mortality.

MeaningThe genetics of race is not important in predicting mortality and length of stay in COVID-19 patients, but age, comorbidities, and insurance status appear to have a significant difference in mortality and length of stay.